Pulnovo PADN cuts clinical worsening by 51% in 264-patient PH-LHD trial
Pulnovo’s randomized PADN-HF-PH study found a 51% reduction in clinical worsening with pulmonary artery denervation plus medical therapy, with results published in NEJM.
Medical Devices & Diagnostics